Canada's Rubicon Organics Eyes Global Stage with European Push

VANCOUVER, BC – April 09, 2026 – Rubicon Organics, a dominant force in Canada's premium cannabis market, is signaling a major strategic pivot towards international expansion. The company announced this week that its top executives will take the stage at three prominent European cannabis conferences in Berlin and London throughout April, a clear move to translate its domestic success into a global footprint.

The Vancouver-based producer is dispatching its leadership to the Talman House Berlin, the International Cannabis Business Conference (ICBC) in Berlin, and the Global Cannabis Regulatory Summit (GCRS) in London. The agenda is not merely about presence; it's about positioning. CEO Margaret Brodie is scheduled to speak on navigating the pitfalls of global cannabis investments, while COO Melanie Ramsey will share insights on building effective international branding strategies. This concerted effort underscores a deliberate strategy to engage with investors, regulators, and potential partners as the company evaluates its entry into Europe’s burgeoning medical cannabis sector.

From Canadian Leader to Global Contender

Rubicon Organics' international ambitions are built on a solid foundation of domestic market leadership. The company has carved out a commanding position in Canada's competitive landscape, not in the crowded, low-margin value segment, but in the lucrative premium and super-premium categories. Financial reports from 2025 solidify this claim, identifying Rubicon as Canada's top premium licensed producer with an 8.0% market share in that segment.

This leadership is driven by a portfolio of trusted brands. Its 1964 Supply Co.™ brand has become the number one selling premium brand in Canada, accounting for a staggering 63% of the company's sales in 2025. This success is complemented by its flagship certified organic brand, Simply Bare™ Organics, which leverages the company's unique cultivation methods as one of the few licensed producers in Canada using living soil. This commitment to organic and sustainable practices provides a key differentiator that the company believes will resonate strongly in health-conscious European markets.

The company’s dominance extends across various product formats, holding significant market share in premium vapes (18.7%), edibles, and topicals. This proven ability to build brand equity and consumer loyalty in a federally regulated market gives Rubicon significant credibility as it looks to export its model abroad.

Targeting Europe's Green Awakening

The timing of Rubicon's European tour is no coincidence. The continent, particularly Germany, is at the forefront of a medical cannabis boom. The European medical cannabis market, valued at over USD 3 billion in 2025, is projected to surge to more than USD 13 billion by 2034. This explosive growth is fueled by progressive legislation and increasing patient access.

Germany stands as the epicenter of this transformation. The country's recent Cannabis Act (CanG), which came into force on April 1, 2024, effectively de-narcotized medical cannabis and streamlined the prescription process. Physicians can now prescribe cannabis-based medicines more freely, and public health insurance reimbursement remains in place, factors that have already contributed to a significant increase in prescription volumes. With an estimated market value approaching $1 billion, Germany is the largest and fastest-growing medical cannabis market outside of North America.

The United Kingdom also represents a key target, with a rapidly expanding patient base now exceeding 100,000 people, largely driven by telehealth platforms. By participating in conferences in Berlin and London, Rubicon is placing itself directly at the heart of Europe’s two most dynamic cannabis markets, aiming to capture a share of this rapid growth.

A Strategy of Branding, Regulation, and Investment

Rubicon's conference agenda reveals a sophisticated, multi-pronged strategy for market entry. The speaking topics chosen for its executives go beyond simple product showcases, addressing the core challenges of global expansion: capital, branding, and compliance.

CEO Margaret Brodie’s panel on navigating investment pitfalls at Talman House Berlin is particularly timely. The global cannabis investment climate has matured, shifting from a 'growth-at-all-costs' frenzy to a 'profitability-first' mandate. Investors are now wary of speculative plays and are seeking companies with proven operational strength and a clear path to positive cash flow. By addressing this topic, Rubicon positions itself as a savvy and reliable operator, appealing to the patient, strategic capital now flowing into the European sector.

Meanwhile, COO Melanie Ramsey's presentation on international branding at ICBC Berlin tackles the next critical hurdle. Building brand recognition in new cultural and regulatory contexts is a complex task. Rubicon plans to leverage the reputation of its successful Canadian brands, with a planned international launch of 1964 Supply Co.™ in 2026. This follows initial test shipments to Poland and Australia in 2025, which allowed the company to gather market intelligence and refine its export logistics. The company has already taken concrete steps, officially launching the 1964 Supply Co.™ brand in the UK this month.

Finally, the company's attendance at the Global Cannabis Regulatory Summit in London highlights its commitment to understanding and navigating the complex patchwork of rules governing European markets. This focus on compliance is essential for building a sustainable, long-term business across multiple jurisdictions.

Powering Expansion with Production and Profitability

A global strategy is only as strong as the operational and financial foundation supporting it. Rubicon Organics has spent the past year bolstering both. The company's 2025 acquisition of the 47,500-square-foot Cascadia indoor facility in Hope, British Columbia, is a cornerstone of its expansion plan. This new facility is set to increase the company's annual production capacity by approximately 40%, from 11,000 kg to a combined 15,500 kg.

The first harvests from Cascadia were completed in February 2026, with revenue from the new facility expected to come online in the first half of the year. This increased capacity provides the necessary supply to service both its growing domestic demand and its new international ventures without compromising either.

This operational expansion is backed by robust financial health. In 2025, Rubicon reported record net revenue of $59.5 million, a 22% increase year-over-year, and generated positive Adjusted EBITDA of $5.0 million. More importantly, it achieved $1.8 million in income from operations, a significant turnaround from a loss the previous year. This disciplined execution and proven profitability set Rubicon apart from many of its peers and provide the financial stability required to fund its international ambitions. As the company prepares to introduce its premium, certified organic cannabis to a global audience, it does so from a position of operational strength, financial stability, and proven brand power.